Placeholder Banner

BIO Files Amicus Brief on Case Addressing Unfairness or Imbalance in Post-Grant Proceedings at PTO (U.S. Court of Appeals for the Federal Circuit)

April 9, 2018

BIO and the Pharmaceutical Research and Manufacturers of America (PhRMA) filed an amicus brief in Virnetx Inc. v. The Mangrove Partners Master Fund, Ltd., Apple Inc., and Black Swamp IP, LLC at the U.S. Court of Appeals for the Federal Circuit.

Biotechnology and pharmaceutical businesses and entrepreneurs rely on the validity and enforceability of their patents to develop innovative products to address unmet medical needs, increase crop yields, and fight disease, hunger, and pollution. Without the promise of effective and predictable patent rights, the investment in the development of these products would be far more difficult – if not impossible – to undertake.

BIO and PhRMA are interested in the outcome of the case because they have a strong interest in preventing unfairness or imbalance in post-grant proceedings at the Patent and Trademark Office (PTO), including instances where such proceedings are improperly instituted or multiple parties improperly joined to the detriment of the patent owner. BIO and PhRMA urge the court to hold that non-compliance with the one-year time limit for properly filing an IPR petition set forth in 35 U.S.C. § 315(b) bars a petitioner from being joined to an ongoing IPR under 35 U.S.C. § 315(c).

Related Resources
BIO PhRMA Brief ECF 62
Discover More
BIO and AUTM have filed an amicus brief in petition for a writ of certiorari the in American Axle & Manufacturing, Inc., v. Neapco Holdings LLC, et al., at the Supreme Court of the United States. BIO and AUTM are concerned that…
BIO files amicus brief in support of a petition for rehearing related to patent-eligibility of diagnostic technology. 
BIO files an Amicus Brief on rehearing by the Precedential Opinion Panel of the Patent Trial and Appeal Board.